G57321FI
| Organisms | Evidence |
|---|---|
| Ovis aries (sheep) | |
| Cricetulus griseus (Chinese hamster) | |
| Mus musculus (house mouse) | |
| Bos taurus (domestic cattle) | |
| Escherichia coli |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
| B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
|---|---|---|---|---|
| GCNT1 | UDP-GlcNAc |
|
[alpha]-1-p-nitrophenyl | |
| GCNT4 | UDP-GlcNAc |
|
[alpha]-1-p-nitrophenyl | |
| GCNT3 | UDP-GlcNAc |
|
[alpha]-1-p-nitrophenyl | |
| B3GNT8 | UDP-GlcNAc |
|
[alpha]-pNp | |
| B3GNT2 | UDP-GlcNAc |
|
[alpha]1-OBn |
| Pathway Name | Organism |
|---|---|
| Lectin pathway of complement activation | Bos taurus |
| Lectin pathway of complement activation | Rattus norvegicus |
| Lectin pathway of complement activation | Mus musculus |
| Lectin pathway of complement activation | Homo sapiens |
| Lectin pathway of complement activation | Xenopus tropicalis |
| Lectin pathway of complement activation | Gallus gallus |
| Lectin pathway of complement activation | Canis familiaris |
RES 1b:a-dgal-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
| PubMed ID | Title | First Author | Publication Date | Source |
|---|---|---|---|---|
| 35132862 | Simultaneously Identifying and Distinguishing Glycoproteins with O-GlcNAc and O-GalNAc (the Tn Antigen) in Human Cancer Cells | Xu S | 2022 Feb 08 |
|
| 35130274 | Cooperativity of catalytic and lectin-like domain of Trypanosoma congolense trans-sialidase modulates its catalytic activity | Waespy M | 2022 Feb 07 |
|
| 36561077 | Targeted protein degradation using the lysosomal pathway | Ghosh S | 2022 Dec 14 |
|
| 35961667 | Monosaccharide profiling of glycoproteins by capillary electrophoresis with contactless conductivity detection | Tomnikova A | 2022 Aug 27 |
|
| 36000290 | A novel splicing variant in GALNS in mucopolysaccharidosis IVA and the necessity of re‐evaluating primer sequences | Kim S | 2022 Aug 24 |
|
| 35997897 | Therapeutic siRNA: State-of-the-Art and Future Perspectives | Friedrich M | 2022 Aug 23 |
|
| 35962937 | Identification of ADP/ATP Translocase 1 as a Novel Glycoprotein and Its Association with Parkinson’s Disease | Zhang W | 2022 Aug 13 |
|
| 35913650 | Studies on the partial characterization of extracted glycosaminoglycans from fish waste and its potentiality in modulating obesity through in-vitro and in-vivo | V G | 2022 Aug 01 |
|
| 35477154 | ABO genotype alters the gut microbiota by regulating GalNAc levels in pigs | Yang H | 2022 Apr 27 |
|
| 35446989 | Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported | Bins S | 2022 Apr 21 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.3.0
Last updated: August 4, 2025